Joseph S. Zakrzewski

CIK: 0001331852

Transaction Breakdown

Open Market Buys (P)3 (21.4%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ANTX

AN2 Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (14 total)

ANTX
AN2 Therapeutics, Inc.
Aug 14, 2026
Gift(G)
Indirect
405.9K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
23.7K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
100K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
10.4K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
10.4K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Disposition(D)
Stock Option (right to buy)
Direct
100K shares-
ANTX
AN2 Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (right to buy)
Direct
23.7K shares-
ANTX
AN2 Therapeutics, Inc.
Feb 20, 2026
Award(A)
Stock Option (Right to Buy)
Direct
20.4K shares-
ANTX
AN2 Therapeutics, Inc.
May 22, 2025
Award(A)
Stock Option (Right to Buy)
Direct
19.1K shares-
ANTX
AN2 Therapeutics, Inc.
Apr 10, 2025
Award(A)
Direct
10.5K shares-
ANTX
AN2 Therapeutics, Inc.
Dec 19, 2024
Award(A)
Direct
9.8K shares-
ANTX
AN2 Therapeutics, Inc.
Nov 27, 2024
Purchase(P)
Direct
2K shares at avg. $1.40$3K
ANTX
AN2 Therapeutics, Inc.
Nov 19, 2024
Purchase(P)
Direct
5K shares at avg. $1.01$5K
ANTX
AN2 Therapeutics, Inc.
Nov 18, 2024
Purchase(P)
Direct
20K shares at avg. $1.00$20K

		Type	Shares	Price		Ownership
Aug 14, 2026	ANTX AN2 Therapeutics, Inc.	Gift(G)	405,880	-	$0	Indirect
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	23,742	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	99,999	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	10,362	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	10,362	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Disposition(D) Stock Option (right to buy)	99,999	-	-	Direct
Mar 19, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (right to buy)	23,742	-	-	Direct
Feb 20, 2026	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	20,400	-	-	Direct
May 22, 2025	ANTX AN2 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,111	-	-	Direct
Apr 10, 2025	ANTX AN2 Therapeutics, Inc.	Award(A)	10,523	-	-	Direct
Dec 19, 2024	ANTX AN2 Therapeutics, Inc.	Award(A)	9,816	-	$0	Direct
Nov 27, 2024	ANTX AN2 Therapeutics, Inc.	Purchase(P)	2,000	$1.40	$2,800	Direct
Nov 19, 2024	ANTX AN2 Therapeutics, Inc.	Purchase(P)	5,000	$1.01	$5,050	Direct
Nov 18, 2024	ANTX AN2 Therapeutics, Inc.	Purchase(P)	20,000	$1.00	$19,996	Direct

1-14 of 14 transactions

About Zakrzewski Joseph S

Zakrzewski Joseph S (SEC CIK 0001331852) files insider reports with the SEC as Director of AN2 Therapeutics, Inc. (ANTX).

Signal8 holds 8 ownership filings by Zakrzewski Joseph S, all Form 4s, filed between Nov 20, 2024 and Aug 14, 2026. Those filings report 14 transactions, from Nov 18, 2024 to Aug 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zakrzewski Joseph S's filings is in MENLO PARK, CA.

Recent filings by Zakrzewski Joseph S

Aug 14, 2026: Gift of ANTX shares (Form 4, code G).
Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).
Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).

Other insiders filing for AN2 Therapeutics, Inc. (ANTX)

Marks Gilbert Lynn, Director
Martin Patricia A., Director
Aziz Kabeer, Director
Trenor Cameron C. III, Chief Medical Officer
Readnour Robin Shane, Director
Williams Sarah Joanne, Principal Accounting Officer

How to read Form 4 transaction codes